Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME
We were motivated to do this study purely because of our experience, Joseph F
Preparation 2 soft cleavage: To a 40 mL glass scintillation vial, add resin bound Preparation 2 (3.06 g, 1.12 mmol) and 30 mL of 30% HFIP DCM solution where a red color change is observed
On-treatment analysis showed weight loss of 22.7% with CagriSema, approaching the efficacy of bariatric surgery
additional injections of vitamin B12 on the same day as pemetrexed or pralatrexate treatments as needed
Factors like food access, safe housing, living wages, high-quality healthcare, and coverage for dietitians all matter just as much